openPR Logo
Press release

Lifitegrast Ophthalmic Solution Market Segments and Key Trends 2016 - 2024

01-19-2018 02:02 PM CET | Health & Medicine

Press release from: Transparency Market Research

Lifitegrast Ophthalmic Solution Market Segments and Key Trends

Lifitegrast Ophthalmic Solution Market: Overview

Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in the eye. Across the world, over 300 million people are reckoned to be suffering from this condition.

Dry eye disease (DED) involves pain, redness, light sensitivity, blurred vision, burning, and inflammation. The primary factors for DED include dry environment, allergy, sun exposure, smoke exposure, heat or chemical burns, aging, previous surgery, contact lenses or infection. At present, there are several treatment approaches available for managing dry eye syndrome, which includes lubricant treatments, anti-inflammatory treatments, autologous serum eye drops, and surgery.

The report presents a comprehensive evaluation of the Xiidra market. This includes analyzing the historic and current performance of the market for future estimates of the growth trajectory of the market.

Obtain Report Details @ https://www.transparencymarketresearch.com/lifitegrast-ophthalmic-solution-market.html

The assessment of the vendor landscape makes for an interesting read as analysts have not only mentioned the top players in the market but have also profiled them in detail. Vital aspects such as business overview, business strategies, product portfolio, financial standing, and recent developments have been taken into consideration to assess the performance of the top players during the forecast period. Using SWOT analysis, readers are provided a clear understanding of the indicators of strengths, weakness, opportunities, and threats of each of the company.

Lifitegrast Ophthalmic Solution Market: Drivers and Restraints

The rising prevalence of dry eye syndrome (DES) across the world is the primary factor attributable to the growth of the Lifitegrast ophthalmic solution market. Diabetes, rheumatoid arthritis, thyroid disorders, lupus, and vitamin A deficiency are some of the underpinning factors that are accounted for the increasing prevalence of dry eye syndrome.

Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13844

Being the first to receive FDA approval for treating the sign as well as symptoms of DES, the Xiidra market is expected to rise exponentially in the near future. The increasing demand for advanced treatment options for DES is expected to be favorable for the growth of the Lifitegrast ophthalmic solution market. The rising geriatric population across the world that is prone to several health conditions also accounts for the high prevalence of dry eye syndrome as a secondary condition.

Dry eye syndrome was earlier not considered seriously as it did not affect everyday functioning. However, the rising awareness about the ill-effects of dry eye syndrome is expected to favor the market’s growth exponentially. Moreover, increasing awareness about the management of this condition is further assisting the market’s growth.

In present times, high level of pollution and rising industrialization is often an underlying factor for the rising prevalence of dry eye disease. However, with rising awareness about the diagnosis and treatment of the disorder will augment the growth of Xiidra market.

Despite the increasing prevalence of dry eye disease, the underdiagnosis of the condition is restraining the market’s growth. Moreover, the trend among patients to render self-medication remains a major restraint for the growth of the Xiidra market.

Pre-Book Full Report @ https://www.transparencymarketresearch.com/checkout.php?rep_id=13844<ype=S

Major Companies Mentioned in Report

Some of the key players in the global market for dry eye syndrome include Novartis AG, Allergan Inc., Cellzome GmbH, NicOx SA, Bridge Pharma Inc., and Santen Pharmaceutical Co. Ltd.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lifitegrast Ophthalmic Solution Market Segments and Key Trends 2016 - 2024 here

News-ID: 909464 • Views:

More Releases from Transparency Market Research

Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights for the USD 15.9 Bn Market 2022-2031
Handheld Marijuana Vaporizer Market Key Drivers, Market Research, and Insights f …
The global handheld marijuana vaporizer market has witnessed remarkable growth in recent years, attributed to the increasing acceptance of medicinal marijuana and the demand for convenient and discreet consumption methods. Valued at US$ 5 billion in 2021, the market is projected to surge at a CAGR of 13.4% to reach US$ 15.9 billion by 2031. This article delves into the factors driving this growth, the evolving market landscape, and the
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And Competitors
Disinfectant Wipes Market Forecast 2020-2030 - Market Size, Drivers, Trends, And …
The COVID-19 pandemic has precipitated a remarkable surge in the demand for disinfectant products, with a notable emphasis on disinfectant wipes as an essential tool in maintaining hygiene and preventing the spread of pathogens. This research report delves into the multifaceted landscape of the disinfectant wipes market, elucidating key trends, drivers, and innovations shaping the industry. 𝐆𝐞𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐫𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐫𝐞𝐩𝐨𝐫𝐭 @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=70359 Key Players and Market Developments Key players
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Study
Tissue Banking Market is Expected to Reach US$ 2,903.3 Million to 2026| TMR Stud …
The global 𝐭𝐢𝐬𝐬𝐮𝐞 𝐛𝐚𝐧𝐤𝐢𝐧𝐠 𝐦𝐚𝐫𝐤𝐞𝐭 reached a value of US$ 1,056.4 million in 2017 and is projected to nearly triple to US$ 2,903.3 million by 2026, with a robust Compound Annual Growth Rate (CAGR) of approximately 12.0% from 2018 to 2026. Factors such as increasing awareness about tissue donation, technological advancements, and a growing target patient population are anticipated to propel market growth during this period. Moreover, the market is expected
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
Vascular Closure Devices Market to reach US$ 1 Billion by 2027: TMR Study
This report by Transparency Market Research, Inc. assesses the present state and future growth potential of the global 𝐯𝐚𝐬𝐜𝐮𝐥𝐚𝐫 𝐜𝐥𝐨𝐬𝐮𝐫𝐞 𝐝𝐞𝐯𝐢𝐜𝐞𝐬 𝐦𝐚𝐫𝐤𝐞𝐭. It features a comprehensive executive summary, offering insights into various segments of the market. Additionally, the report provides detailed analysis and data on product, access type, application, end user, and regional segments within the global market. Vascular closure devices is estimated to reach a value of ~US$ 1 Bn

All 5 Releases


More Releases for Lifitegrast

Lifitegrast Ophthalmic Solution Market Size, Status and Forecast to 2024
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in
Lifitegrast Ophthalmic Solution Market to Reflect Impressive Growth Rate During …
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in
Lifitegrast Ophthalmic Solution Market | Analysis and Forecast up to 2024
Lifitegrast Ophthalmic Solution Market: Overview Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick
02-22-2017 | Health & Medicine
TMR
Global Lifitegrast Ophthalmic Solution Market is Driven by Rising Prevalence of …
Lifitegrast, available under the trade name Xiidra is the first U.S. FDA approved drug for treating the signs and symptoms of dry eye syndrome. Dry eye syndrome, also referred to as dry eye disease is a chronic disorder, which is related to lack of tears in order to maintain sufficient moisture in the eye. The condition is either due to less production of tears or quick drying of tears in
02-03-2017 | Health & Medicine
TMR
Lifitegrast Ophthalmic Solution Market: Increasing Demand for Advance Treatment …
Lifitegrast is an integrin antagonist that reduces T-cell-mediated inflammation associated with dry eye disease (DED). This molecule was in pipeline for past few years and several clinical trials have been performed to test its efficacy in treating the signs and symptoms of dry eye syndrome. Avail a Sample of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13844 In July 2016, lifitegrast ophthalmic solution (5%) under the brand name Xiidra by Shire plc was granted an approval from
01-13-2017 | Health & Medicine
TMR
Lifitegrast Ophthalmic Solution Market: Growing Awareness Regarding Dry Eye Synd …
Dry eye syndrome (DES) also called as dry eye disease (DED) or keratoconjunctivitis sicca (KCS), is a chronic disease that leads to lack of tears to maintain sufficient moisture to the eye. This condition is either a sign of less production of tears or quick drying of the film of tears. More than 300 million people are estimated to suffer from this condition. This medical condition is associated with symptoms